Cardiovascular Risks

Prevention

CV prevention: Another look at stories of 2007-the year in review

Mar 11, 2008 12:00 EDT

Drs Weber and Nissen run down and give perspective to heartwire stories on the topic of prevention that were the most important in 2007. Which stories give evidence of progress and which stories have proven controversial? Enjoy their fast moving commentary.

Prevention

Inhibitors of the RAS: Many meta-analyses - but no one answer

2 COMMENTS - Feb 29, 2008 16:00 EST

ACEs, ARBs, combinations. Which is best? Drs Weber, Kostis, Messerli and Gradman discuss recent meta-analyses. Is there a definitive winner?

Prevention

Hypertension and beyond: Highlights from ESH 2007

Jun 29, 2007 12:00 EDT

Hear what the experts have to say about ESH 2007: Join Dr Weber as he discusses topics ranging from microalbuminuria, cardiovascular risk and the new ESH/ESC Hypertension Guidelines with Drs Mancia, Hermida, Meredith, Schmeider, Collier and Lacy.

Prevention

Preventing cardiovascular and renal disease: A clinical update

3 COMMENTS - Jun 22, 2007 15:00 EDT

Angiotensin receptor blockers (ARBs) not only provide blood pressure control but also have important blood pressure-independent benefits. Please join Drs Mancia, Burgess and McInnes as they discuss how ARBs may help to address total cardiovascular risk across the cardiovascular continuum.

Prevention

ACEIs, ARBs and renin inhibitors: How best to block the RAS?

Jun 14, 2007 07:00 EDT

Clinicians now have 3 alternatives to block the complex Renin-Angiotensin-System, as well as the option of combining agents. Does it really matter which option is used? A panel discussion examines this question with Drs Weber, Dzau, Gorelick, and Hollenberg.

Prevention

Late-breaking: The AMADEO trial - a head-to-head comparison of ARBs

3 COMMENTS - May 30, 2007 10:22 EDT

The AMADEO trial: The very first head-to-head comparison of ARBs for differences in proteinuria or kidney disease progression. See how reducing blood pressure in hypertensive diabetics can benefit the kidneys.

Prevention

The relationship between CKD and CVD: Update in target organ protection and cardiovascular risk reduction

May 18, 2007 18:00 EDT

Chronic kidney disease and cardiovascular disease: Double trouble leads to more morbidity and mortality. What new therapies offer promise for patients with chronic kidney disease?

CME provider: The University of Cincinnati College of Medicine.
The Cardiovascular Risks clinical theme is sponsored by the University of Cincinnati, Office of CME, and is supported by an independent educational grant from Boehringer-Ingelheim.

	Yes, vitamin E
	Yes, vitamin C
	Yes, both
	Neither